Good afternoon :)
$
₹
Black Diamond Therapeutics Inc

Black Diamond Therapeutics Inc

BDTX

NASDAQ
Asset Logo

Black Diamond Therapeutics Inc

BDTX

NASDAQ
$1.6512.89% (-0.24)
$
₹
$1.6512.89% (-0.24)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $103.7M the stock is ranked 4652

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

1.04
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-0.75
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 8 analysts reports

Buy
7 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+426.32%

Earnings Growth

-212.46%

Rev. Growth

-91.07%

See Detailed Forecast

Company Profile

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
49.14
49.14
1Y Return
36.01%
36.01%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.64
28.64
1Y Return
50.65%
50.65%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
42.33%
42.33%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.59
35.59
1Y Return
30.09%
30.09%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.51
21.51
1Y Return
40.33%
40.33%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 426.32% growth, versus a trailing 3-year CAGR of -0.17%.

2026
Current$1.9Baseline
Analyst Target - 1 year
Target$10+426.32%

All values in $

202220232024202520262027$3.96$6.31$8.65Target+426.32%
2026
Current$1.9Baseline
Analyst Target - 1 year
Target$10+426.32%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$70Baseline
Forecast for Dec 2026
High$50-28.57%
Average$6.25-91.07%
Low$0-100%

All values in $ Million

202120222023202420252026000070Low-100%Average-91.07%High-28.57%
2025
Current$70Baseline
Forecast for Dec 2026
High$50-28.57%
Average$6.25-91.07%
Low$0-100%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$0.5Baseline
Forecast for Dec 2026
High$-0.01-101.98%
Average$-0.57-212.46%
Low$-0.75-248.84%

All values in $

202120222023202420252026-3.47-2.52-1.88-1.270.5Low-248.84%Average-212.46%High-101.98%
2025
Current$0.5Baseline
Forecast for Dec 2026
High$-0.01-101.98%
Average$-0.57-212.46%
Low$-0.75-248.84%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-8.4
-15.1
-9
-9.9
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0000.517000000
Net Income-18.22-19.90-15.55-15.9856.54-10.56-8.49-15.11-9.03-9.90
Net Profit Margin----3097.86%80.77%-----
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Black Diamond Therapeutics Inc -1.04-
AbbVie Inc49.1450.450.58
Amgen Inc28.6421.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare BDTX with any stock or ETF
Compare BDTX with any stock or ETF
Comparing from
BDTX
ABBV
AMGN
Loading...

Frequently asked questions

  1. Black Diamond Therapeutics Inc (BDTX) share price today is $1.65 as of November 6, 2026 at 2:29 AM IST. The stock touched a day high of $1.88 and a day low of $1.65.

  2. Black Diamond Therapeutics Inc stock trades on NASDAQ under the ticker symbol BDTX.

  3. Black Diamond Therapeutics Inc's market capitalization is $103.71M as of November 6, 2026 at 2:29 AM IST.

  4. Black Diamond Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of November 5, 2026.

  5. Black Diamond Therapeutics Inc's price-to-book (P/B) ratio is 1.04 as of November 5, 2026.

  6. Yes, You can buy Black Diamond Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Black Diamond Therapeutics Inc shares in three steps: 1. Search Black Diamond Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Black Diamond Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Black Diamond Therapeutics Inc (BDTX) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 6.0422 shares at the current price of $1.65.

Loading...